Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05190432
Other study ID # ERGO61222.A1
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 10, 2021
Est. completion date August 2024

Study information

Verified date May 2024
Source University of Southampton
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The complexities of the immune system make measuring the impact of dietary interventions upon its function challenging. The immune system is highly responsive to environmental influences, including the diet. An individual's diet provides the energy required to mount a strong and protective immune response, the building blocks required for synthesis of immune mediators such as antibodies and cytokines, and can also indirectly affect immune function via changes in the gut microbiome. Immune function varies across the lifecourse, with a well understood decline in immune function with age, resulting in impaired vaccination responses and an increased risk of infections and of severe complications and mortality arising from common communicable diseases such as influenza. This impaired immunity with ageing is known as immunosenescence and this affects both innate and acquired arms of the immune system.


Description:

Expert guidance is available to inform the design of human nutrition trials to ensure they include the most relevant immunological outcomes (Albers, 2013). In this study, ex vivo phagocytosis and oxidative burst of immune cells will be the primary outcome, supported by other ex vivo immune measures of high clinical relevance including functional assessment of cytokine production and expression of activation markers. Human nutritional trials frequently omit to monitor the degree of immunosenescence in participants, even amongst studies conducted amongst older adults. For example, a recent review of pre- and probiotic trials which assessed immune responses in older adults identified that only two of thirty-six studies assessed any marker of immunosenescence (Childs & Calder, 2017). Taxifolin/DHQ is a naturally occurring polyphenol found in apples, onions and other fruits and bark extracts. Ergothioneine is an amino acid found in mushrooms, oats and some bean varieties. We hypothesise that Taxifolin/DHQ and/or Ergothioneine will alter immune function via their established antioxidant effects, and that the effects observed will vary between older adults relative to their degree of immunosenescence. Though current dietary guidelines advise consumption of 5 portions of fruits and vegetables per day, recent surveys reveal that fewer than 30% of adults achieve this. Antioxidants found within fruits and vegetables are understood to be one of the important aspects by which our diet can influence health. It is important to investigate the effects of such antioxidants through well designed and conducted human trials.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 90
Est. completion date August 2024
Est. primary completion date September 29, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 65 Years
Eligibility Inclusion Criteria: - age 50-65yr - BMI 18.5-30kg/m2 - Willing to avoid consumption of foods rich in Taxifolin/DHQ and Ergothioneine during the study period - Willing to avoid taking any other food supplements or high doses of vitamins during the study period - Able to provide written informed consent. Exclusion Criteria: - Use of prescription medication which may influence immune function, such as anti-inflammatory or immunosuppressant medication - Diabetes requiring any medication - Liver cirrhosis - A history of drug or alcohol misuse - Asplenia or other acquired or congenital immunodeficiencies - Any autoimmune disease including connective tissue diseases - Malignancy - Laboratory confirmed SARS-CoV-2 infection within last 3 months - self-reported symptoms of acute or recent infection (including use of antibiotics within the last 3 months)

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Taxifolin
A naturally occurring polyphenol found in apples, onions and other fruits and bark extracts.
Ergothioneine
An amino acid found in mushrooms, oats and some bean varieties.
Control
Microcrystalline cellulose.

Locations

Country Name City State
United Kingdom NIHR Southampton Biomedical Research Centre Southampton Hampshire

Sponsors (2)

Lead Sponsor Collaborator
University of Southampton Blue California

Country where clinical trial is conducted

United Kingdom, 

References & Publications (9)

Albers R, Bourdet-Sicard R, Braun D, Calder PC, Herz U, Lambert C, Lenoir-Wijnkoop I, Meheust A, Ouwehand A, Phothirath P, Sako T, Salminen S, Siemensma A, van Loveren H, Sack U. Monitoring immune modulation by nutrition in the general population: identifying and substantiating effects on human health. Br J Nutr. 2013 Aug;110 Suppl 2:S1-30. doi: 10.1017/S0007114513001505. — View Citation

Childs, C. E., & Calder, P. C. (2017). Modifying the gut microbiome through diet: effects on the immune system of elderly subjects. In T. Fulop, C. Franceschi, K. Hirokawa, & G. Pawelec (Eds.), Handbook of Immunosenescence Cham: Springer International Publishing AG. DOI: 10.1007/978-3-319-64597-1_160-1

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Turck D, Bresson JL, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuhauser-Berthold M, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjodin A, Stern M, Tome D, Vinceti M, Willatts P, Engel KH, Marchelli R, Poting A, Poulsen M, Schlatter J, Gelbmann W, Van Loveren H. Scientific Opinion on taxifolin-rich extract from Dahurian Larch (Larix gmelinii). EFSA J. 2017 Feb 14;15(2):e04682. doi: 10.2903/j.efsa.2017.4682. eCollection 2017 Feb. — View Citation

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Turck D, Bresson JL, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuhauser-Berthold M, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjodin A, Stern M, Tome D, Vinceti M, Willatts P, Engel KH, Marchelli R, Poting A, Poulsen M, Schlatter JR, Ackerl R, van Loveren H. Statement on the safety of synthetic l-ergothioneine as a novel food - supplementary dietary exposure and safety assessment for infants and young children, pregnant and breastfeeding women. EFSA J. 2017 Nov 13;15(11):e05060. doi: 10.2903/j.efsa.2017.5060. eCollection 2017 Nov. — View Citation

Ey J, Schomig E, Taubert D. Dietary sources and antioxidant effects of ergothioneine. J Agric Food Chem. 2007 Aug 8;55(16):6466-74. doi: 10.1021/jf071328f. Epub 2007 Jul 6. — View Citation

Kang M, Ragan BG, Park JH. Issues in outcomes research: an overview of randomization techniques for clinical trials. J Athl Train. 2008 Apr-Jun;43(2):215-21. doi: 10.4085/1062-6050-43.2.215. — View Citation

Przemska-Kosicka A, Childs CE, Enani S, Maidens C, Dong H, Dayel IB, Tuohy K, Todd S, Gosney MA, Yaqoob P. Effect of a synbiotic on the response to seasonal influenza vaccination is strongly influenced by degree of immunosenescence. Immun Ageing. 2016 Mar 15;13:6. doi: 10.1186/s12979-016-0061-4. eCollection 2016. — View Citation

Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther. 1974 May;15(5):443-53. doi: 10.1002/cpt1974155443. No abstract available. — View Citation

Vega-Villa KR, Remsberg CM, Ohgami Y, Yanez JA, Takemoto JK, Andrews PK, Davies NM. Stereospecific high-performance liquid chromatography of taxifolin, applications in pharmacokinetics, and determination in tu fu ling (Rhizoma smilacis glabrae) and apple (Malus x domestica). Biomed Chromatogr. 2009 Jun;23(6):638-46. doi: 10.1002/bmc.1165. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Phagocytosis activity by granulocytes ex vivo Mean fluorescence intensity per cell will be assessed by flow cytometry. 8 weeks post intervention
Secondary Percentage phagocytosis by monocytes ex vivo Percentage of cells undergoing phagocytosis will be assessed by flow cytometry. 4 weeks, 8 weeks, 3 months post intervention
Secondary Phagocytosis activity by monocytes ex vivo Mean fluorescence intensity per cell will be assessed by flow cytometry. 4 weeks, 8 weeks, 3 months post intervention
Secondary Percentage phagocytosis by granulocytes ex vivo Percentage of cells undergoing phagocytosis will be assessed by flow cytometry. 4 weeks, 8 weeks, 3 months post intervention
Secondary Phagocytosis activity by granulocytes ex vivo Mean fluorescence intensity per cell will be assessed by flow cytometry. 4 weeks, 3 months post intervention
Secondary Percentage oxidative burst by monocytes ex vivo Percentage of cells undergoing oxidative burst will be assessed by flow cytometry. 4 weeks, 8 weeks, 3 months post intervention
Secondary Oxidative burst activity by monocytes ex vivo Mean fluorescence intensity per cell will be assessed by flow cytometry. 4 weeks, 8 weeks, 3 months post intervention
Secondary Percentage oxidative burst by granulocytes ex vivo Percentage of cells undergoing oxidative burst will be assessed by flow cytometry. 4 weeks, 8 weeks, 3 months post intervention
Secondary Oxidative burst activity by granulocytes ex vivo Mean fluorescence intensity per cell will be assessed by flow cytometry. 4 weeks, 8 weeks, 3 months post intervention
Secondary Frequencies of naive T cells The proportion of naive T cells will be assessed by flow cytometry. 8 weeks
Secondary Frequencies of memory T cells The proportion of memory T cells will be assessed by flow cytometry. 8 weeks
Secondary CD57 expression upon T cells. The proportion of T cells expressing CD57 (a marker associated with chronic immune activation) and the mean fluorescence intensity per cell will be assessed by flow cytometry. 8 weeks
Secondary CD28 expression upon T cells. The proportion of T cells expressing CD28 (a cell surface marker required for T cell activation and survival) and the mean fluorescence intensity per cell will be assessed by flow cytometry. 8 weeks
Secondary Plasma lipid peroxides Participant plasma lipid peroxides will be measured by colorimetric analysis. 8 weeks
Secondary Urinary isoprostanes Participant urinary isoprostanes will be measured by commercially available ELISA. 4 weeks, 8 weeks, 3 months post intervention
Secondary Plasma isoprostanes Participant plasma isoprostanes will be measured by commercially available ELISA. 4 weeks, 8 weeks, 3 months post intervention
Secondary Cytokine production by cryopreserved peripheral blood mononuclear cells in response to lipopolyssaccharide A panel of pro- and anti-inflammatory cytokines secreted by immune cells ex vivo will be assessed by Luminex array. 4 weeks, 8 weeks
Secondary Cytokine production by cryopreserved peripheral blood mononuclear cells in response to influenza or coronavirus vaccine products A panel of pro- and anti-inflammatory cytokines secreted by immune cells ex vivo will be assessed by Luminex array. 4 weeks, 8 weeks
Secondary Metabolomic analysis of urine samples Full metabolic profiling of first-morning urine samples will be used to assess changes to metabolic activity of participants and their microbiome. 4 weeks, 8 weeks, 3 months post intervention
Secondary Metabolomic analysis of serum samples Full metabolic profiling of serum samples will be used to assess changes to metabolic activity of participants. 4 weeks, 8 weeks, 3 months post intervention
Secondary Faecal microbiome analysis Sequences of ribosomal RNA (rRNA) in participant faecal samples will be measured to assess changes in the numbers or proportions of bacterial genera and species/strains. 4 weeks, 8 weeks, 3 months post intervention
Secondary Incidence of self-reported seasonal cold, coronavirus and influenza-like illness. A daily online form will be completed by participants to log any seasonal cold, coronavirus and influenza-like illness. 4 weeks, 8 weeks, 3 months post intervention
Secondary Duration of self-reported illness. A daily online form will be completed by participants to log any self-reported illness. 4 weeks, 8 weeks, 3 months post intervention
Secondary Severity of self-reported illness. A daily online form will be completed by participants to log any self-reported illness. 4 weeks, 8 weeks, 3 months post intervention
Secondary Self-reported medication use. A daily online form will be completed by participants to log any medication use. 4 weeks, 8 weeks, 3 months post intervention
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A